{"name":"Kailera","slug":"kailera","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"KAI-9531","genericName":"KAI-9531","slug":"kai-9531","indication":"Metastatic non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]}],"pipeline":[{"name":"KAI-9531","genericName":"KAI-9531","slug":"kai-9531","phase":"phase_3","mechanism":"KAI-9531 is a small molecule that targets the PD-1 receptor.","indications":["Metastatic non-small cell lung cancer, PD-L1 positive","Metastatic melanoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPMFVid0NnUVd3RU9Ib0lhZWg5SnBmeTFqLXZ6akVtR2E0WElOZGExNjNQZ3RFcWlxOEppUjVud250azE2Vmc1cGdnWFN6YUV4Vzk2YlpJN29kSGhVTHBCXy1MSVJnU0dybVNwb1N4VkxyQjJxVW8yMkJaQkw2N2lDcmlOSzlCbmM?oc=5","date":"2026-03-30","type":"pipeline","source":"pharmaphorum","summary":"Obesity-focused biotech Kailera joins IPO queue in US - pharmaphorum","headline":"Obesity-focused biotech Kailera joins IPO queue in US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE55UHU1bzJFNmpuZW9fYkZ4WmxlYzdRdEVUaXk4SU5ldzZPS1dvdzEyOEhLcU1kMDh0dnl1bG1kSzUtQkZnRjRoWTYzVXY0WkdjaFA0UkpRaEpfN01WTVA3MXFGLUpsV2VsbUR6bkxuVGV6Mzl1?oc=5","date":"2026-02-11","type":"pipeline","source":"The Pharma Letter","summary":"Kailera Therapeutics - The Pharma Letter","headline":"Kailera Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNMGhxWlVSM2wzdUNBZFM3bUl5b2VqNW01YlN5bmtkSUZ2ZFJPWTFvX3pnRGg0WGF5ekRiU1d2ZGQyTVljdjVtU1lPalJ1N0RfWmFOanUxa3J0WWR5c0ZOVWtOMmVCNlpMdzFHSlVuNFZ2WGdvaDBNbngwQkswajVOaGJwXy1Teml1anZoZGxfa1hWdw?oc=5","date":"2026-02-10","type":"trial","source":"Yahoo Finance","summary":"Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide - Yahoo Finance","headline":"Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxObHotbUh3QUFiLXZPOF81QWdKdzdwRlQxZlNLM2hheVdyN3JxeTJhQXRpbnNpXzZReU5EUElFcDZkQy1RbTVHLUlYUVl1VmVQeGRKUnNaMTlVbWlrWmJYczBVMXVZak1wNEpIVmVFTEgxRU9xZXB3M0dndUxvYUVnSUlCcGVtSUwzcnVWVXNvZmVtZ2ZPSlk5Q3pQLUpLbmpuenZWOEtEOVlfYWd3cmFYdmZiR1o0ZWdLVFJ6eUppWUNsYUF3MHZJa2Vn?oc=5","date":"2026-02-10","type":"trial","source":"BioSpace","summary":"Kailera, Hengrui Push Oral GLP-1/GIP Pill to Phase 3 After Clearing Mid-Stage China Study - BioSpace","headline":"Kailera, Hengrui Push Oral GLP-1/GIP Pill to Phase 3 After Clearing Mid-Stage China Study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNakxNa0JTWW9yVnZQNS1yMHlzdjROdFFNX1hoX0I1TkVnWFY4bmhaaUJFZFc5SGhIMnVUaDB1OTBwZXc5dFkwdzdHdkFHd0pjOEhENzFwQTA2aFJCMWN0eE1BQUl1YVJ2VEYxMkYtbXNsUmU3NkxtbzFYWmk1UmxoTHlWZXJnRGYzc2xZ?oc=5","date":"2026-02-10","type":"pipeline","source":"pharmaphorum","summary":"Kailera, Hengrui stake claim to oral weight loss category - pharmaphorum","headline":"Kailera, Hengrui stake claim to oral weight loss category","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNc1FwempzbWtNQTJQMFlueWZoZ1RMeGxjQjQ3WGp2ZDF0ZjF5bmlnUFR2RTI5WHREWl8wd0FnT1l3WnlTUDNlQXM5OFhDYUQ3TkRzZndDeFpSenZvMVdZYURYZFI5Vlo2d2NKT1dvNG5fT01SbEJQdXl4dHhKT1ZaeTh1elViVF9vVmwwNXZJbzFZalJjaXBtY2pn?oc=5","date":"2026-02-09","type":"pipeline","source":"BioPharma Dive","summary":"Hengrui, Kailera tout positive results for dual-acting obesity pill - BioPharma Dive","headline":"Hengrui, Kailera tout positive results for dual-acting obesity pill","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNLWpFTzhYNjJyYzdYUTYzaklaNUNpbjlVR0UxbmU4WGd5TERqb3hGVkd4bkVSbDVpRzNvSUdQQm5LNlA5aUxmUTlZRlUycGExZV84aTA5T04zMTJhUmhLTEozbkVsdmw4RFl4WDJSVjNJWGJBOTF2QXg4ell6b1ZKNXNMdmdJcUdqb3QydFFpaEd2UQ?oc=5","date":"2026-01-20","type":"pipeline","source":"BioPharma Dive","summary":"Kailera’s Ron Renaud on how a China-linked startup can compete in obesity - BioPharma Dive","headline":"Kailera’s Ron Renaud on how a China-linked startup can compete in obesity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwJBVV95cUxQVGFUSEpxTE0wSjE1TWZlcVNaclVaWFB0bXpQYVZpeFZLdEpwYUpBVEk4NVRoRkpFYU50cm15enpLZU56NXR6QklNdE5mUkVtZ203UHQxRmtWOXlHRzNOdF9ZSGRiVENIQ0hoblE3RUhaNkVnT0pPd0tTV2U4enNtdUpYRXVYRWtOcjNQUUdHS3Q3M0NHS19Yem5ONkVGVndPMWI3am1vSlZHUmJzamJ0NWFpRDQ3UTFGRUJ5b0tSeDlKb0l3VXZBTUtyVXhnV0xaQVRQN0xMYkJqNEJiaTJpVWVwem9SakhLSnYwaXN5WlJUT0o4VEZTZjJSOHlfQzU3bmluMEVZZ1lfUWE0Z015OXJrZlV1Y3ZaQjlrWEw1VmVQVGZ2M2c2a01JMnQ4Mlpxcl91UEdWUl8xdUk?oc=5","date":"2025-11-04","type":"trial","source":"GlobeNewswire","summary":"Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531 - GlobeNewswire","headline":"Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP R","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNS0M3U2V6eDZTbmsxR1ZrNENXa3dqb3Z2alktam9PUld5NE1EVWxsYzBDRnN3MVlXbTdreVdrVGxOR25WamkwNnpRcW9XRFNzeWxYQVJQSjdyUFZYSEstWGYxeVBCVzllVWJMbzZobm9tUldrUWlPa1V2VW9qTm1zNnpoRnJkOXdNbGJ1WkR3VXJTSHNiRU41SnR3Mk9YSGIyYU40T3l1MndQSjA?oc=5","date":"2025-10-14","type":"trial","source":"fiercebiotech.com","summary":"Kailera taps Bain-led syndicate for $600M to carry Zepbound challenger into phase 3 - fiercebiotech.com","headline":"Kailera taps Bain-led syndicate for $600M to carry Zepbound challenger into phase 3","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPTEZuSDlhcWxuMGsxeTRPVmFqYjlwMXM3bDN2UGwwVGw2dWhfX093cWlObGdfSUR5ZUxiY05fLUhhSElhdE1NdGtVN1dodmY4S0plSDR6b3hmWUhOZ2p1U2hfWDR4MmNWckpHMjVsZFlwdFVlWEVUQnFybWdqYjR2S3FwblNfdU9mUnRHVWpyNHVINjNkODBiWWlGSThnZ25NcEswQlRwMkladmM?oc=5","date":"2025-10-14","type":"trial","source":"Pharmaceutical Technology","summary":"Kailera nets $600m to power Phase III launch of obesity drug - Pharmaceutical Technology","headline":"Kailera nets $600m to power Phase III launch of obesity drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9QdHU2dUlkQU1VbUVNX3VxNFQ1WnFlTVlwekk2aHFWbHl4UE5rd3FtTTR1a0U4QURyUjJfczRyd1paMUVJMmFwbDRxNElZMnBuSDNj?oc=5","date":"2025-07-15","type":"trial","source":"FirstWord Pharma","summary":"Hengrui, Kailera obesity drug clears Phase III hurdle, China filing planned - FirstWord Pharma","headline":"Hengrui, Kailera obesity drug clears Phase III hurdle, China filing planned","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQWm1iLTFSQ2xWT2RsWUxkNEp5RExmM0NMU1AxZkEydU9VNGNTTWpwOWlTMkZTQncyTTNZU1FmZzJwMHdfb1Y4aTRlVmN1TGN0UklpUmtGc3l4STlyNk9QcGhVZ2NXajVJZXdQeXVWZHZkZ1lMVm5BSk03bWxVVENHeDNPZVo3X0JPYmE4MjY0R0ZnTjNGb0daQWM4a1R2dw?oc=5","date":"2025-07-15","type":"trial","source":"MedCity News","summary":"Hengrui Pharma’s Potential Rival to El Lilly’s Zepbound Leads to 18% Weight Loss in Key Study - MedCity News","headline":"Hengrui Pharma’s Potential Rival to El Lilly’s Zepbound Leads to 18% Weight Loss in Key Study","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}